Overview

Welcome to Stayble Therapeutics AB´s IR pages

Stayble Therapeutics is a clinical stage pharmaceutical company developing STA363, an intradiscally injected formulation against chronic discogenic low back pain. STA363 is intended for patients not improving after treatment with analgesics and physiotherapy.

LATEST PRESS RELEASES

07 October 2020

Stayble presents at EUROSPINE Annual Meeting 2020

Stayble Therapeutics today announced that Professor Anders Lehmann, VP Development, will give a talk entitled ”Sclerosation of the intervertebral disc using lactic acid in patients with discogenic c...

06 October 2020

Stayble initiates clinical phase 2b study in Spain

Stayble Therapeutics today announced that the Company has initiated the first clinic in Spain for its clinical phase 2b study with the drug candidate STA363. Patient recruitment will commence immediat...

FINANCIAL CALENDAR

Interim report Q3 2020
16November2020
Interim report Q4 2020
15February2021